By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b ...

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased ...

SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a ...

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Mesenchymal Stem Cells-Derived Exosomes is under clinical development by AbelZeta and currently in Phase II for Acute Respiratory Distress Syndrome.

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...

Celebrate advancements in bone marrow transplantation in India, offering hope and life-saving treatments for patients ...

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its ...

The global cell therapy manufacturing industry is poised for rapid growth, with a projected valuation of USD 4,134.48 million ...